Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and ...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see ...

Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

In a report released today, Akash Tewari from Jefferies assigned a Buy rating to Pfizer (PFE – Research Report), with a price target of ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

The Pfizer-sponsored study enrolled 187 participants across the world — including 10 from Oregon Health & Science University, ...

Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, ...

Ponsegromab, a monoclonal antibody treatment from Pfizer, showed promising results in a clinical study aimed at treating the wasting condition cachexia in cancer patients. Patients treated with ...

14 in the New England Journal of Medicine. Ponsegromab is a monoclonal antibody created by Pfizer that targets growth differentiation factor-15. The study involved 187 patients with non-small cell ...

Results for Pfizer’s ponsegromab looked promising, while BioNTech and Instil Bio capitalized on momentum surrounding a kind of bispecific antibody.